Last reviewed · How we verify
NPT088
At a glance
| Generic name | NPT088 |
|---|---|
| Also known as | IgG1, fusion protein, GAIM, anti-Abeta, anti-Tau |
| Sponsor | Proclara Biosciences, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Multiple Dose Safety Study of NPT088 in Patients With Mild to Moderate Probable Alzheimer's Disease (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NPT088 CI brief — competitive landscape report
- NPT088 updates RSS · CI watch RSS
- Proclara Biosciences, Inc. portfolio CI